Pfizer (PFE) Gains from Investment Securities (2009 - 2026)

Pfizer (PFE) has 18 years of Gains from Investment Securities data on file, last reported at -$22.0 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$22.0 million, down 114.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 billion (up 2366.67% YoY), and the FY2025 annual result was $4.7 billion, up 1556.54% from the prior year.
• Gains from Investment Securities retreated to -$22.0 million in Q1 2026 per PFE's latest filing, from $5.0 billion in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $5.0 billion in Q4 2025 and troughed at -$2.3 billion in Q4 2023.
• A 5-year average of $282.7 million and a median of $13.0 million in 2024 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities slumped 400.0% in 2022, then surged 1195.0% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at $200.0 million in 2022, then slumped by 1246.5% to -$2.3 billion in 2023, then soared by 100.57% to $13.0 million in 2024, then surged by 38284.62% to $5.0 billion in 2025, then slumped by 100.44% to -$22.0 million in 2026.
• Business Quant data shows PFE's Gains from Investment Securities at -$22.0 million in Q1 2026, $5.0 billion in Q4 2025, and -$14.0 million in Q3 2025.